Passive immunity - wikipedia Passive immunity Passive immunity is the transfer of active humoral immunity in the form of ready - made antibodies. Passive immunity can occur naturally, when maternal antibodies are transferred to the fetus through the placenta, and it can also be induced artificially, when high levels of antibodies specific to a pathogen or toxin ( obtained from humans, horses, or other animals ) are transferred to non-immune persons through blood products that contain antibodies, such as in immunoglobulin therapy or antiserum therapy. Passive immunization is used when there is a high risk of infection and insufficient time for the body to develop its own immune response, or to reduce the symptoms of ongoing or immunosuppressive diseases. Passive immunization can be provided when people can not synthesize antibodies, and when they have been exposed to a disease that they do not have immunity against. Contents 1 Naturally acquired 2 Artificially acquired 2.1 History and applications of artificial passive immunity 2.2 FDA licensed immunoglobulins 3 Advantages and disadvantages 4 See also 5 References Naturally acquired Maternal passive immunity is a type of naturally acquired passive immunity, and refers to antibody - mediated immunity conveyed to a fetus or infant by its mother. Naturally acquired passive immunity can be provided during pregnancy, and through breastfeeding. In humans, maternal antibodies ( MatAb ) are passed through the placenta to the fetus by an FcRn receptor on placental cells. This occurs predominately during the third trimester of pregnancy, and thus is often reduced in babies born prematurely. Immunoglobulin G ( IgG ) is the only antibody isotype that can pass through the human placenta, and is the most common antibody of the five types of antibodies found in the body. IgG antibodies protects against bacterial and viral infections in fetuses. Immunization is often required shortly following birth to prevent diseases in newborns such as tuberculosis, hepatitis B, polio, and pertussis, however, maternal IgG can inhibit the induction of protective vaccine responses throughout the first year of life. This effect is usually overcome by secondary responses to booster immunization. Passive immunity is also provided through colostrum and breast milk, which contain IgA antibodies that are transferred to the gut of the infant, providing local protection against disease causing bacteria and viruses until the newborn can synthesize its own antibodies. Maternal antibodies protect against some diseases more than others such as measles, rubella, and tetanus compared to the protection provided against polio, and pertussis. Maternal passive immunity offers immediate protection, though protection mediated by maternal IgG typically only lasting four to six months after birth. Protection mediated by IgA is dependent on the length of time that an infant is breastfed, which is one of the reasons the World Health Organization recommends breastfeeding for at least the first two years of life. Only a few other species besides humans transfer maternal antibodies before birth, including primates and lagomorphs ( which includes rabbits and hares ). In some of these species IgM can be transferred across the placenta as well as IgG. All other mammalian species predominantly or solely transfer maternal antibodies after birth through milk. In these species, the neonatal gut is able to absorb IgG for hours to days after birth. However, after a period of time the neonate can no longer absorb maternal IgG through their gut, an event that is referred to as `` gut closure ''. If a neonatal animal does not receive adequate amounts of colostrum prior to gut closure, is does not have a sufficient amount of maternal IgG in its blood to fight off common diseases. This condition is referred to as failure of passive transfer. It can be diagnosed by measuring the amount of IgG in a newborn 's blood, and is treated with intravenous administration of immunoglobulins. If not treated, it can be fatal. Artificially acquired See also : Temporarily induced immunity Artificially acquired passive immunity is a short - term immunization achieved by the transfer of antibodies, which can be administered in several forms ; as human or animal blood plasma or serum, as pooled human immunoglobulin for intravenous ( IVIG ) or intramuscular ( IG ) use, as high - titer human IVIG or IG from immunized donors or from donors recovering from the disease, and as monoclonal antibodies ( MAb ). Passive transfer is used to prevent disease or used prophylactically in the case of immunodeficiency diseases, such as hypogammaglobulinemia. It is also used in the treatment of several types of acute infection, and to treat poisoning. Immunity derived from passive immunization lasts for a few weeks to three to four months. There is also a potential risk for hypersensitivity reactions, and serum sickness, especially from gamma globulin of non-human origin. Passive immunity provides immediate protection, but the body does not develop memory, therefore the patient is at risk of being infected by the same pathogen later unless they acquire active immunity or vaccination. History and applications of artificial passive immunity A vial of diphtheria antitoxin, dated 1895 In 1888 Emile Roux and Alexandre Yersin showed that the clinical effects of diphtheria were caused by diphtheria toxin and, following the 1890 discovery of an antitoxin - based immunity to diphtheria and tetanus by Emil Adolf von Behring and Kitasato Shibasaburō, antitoxin became the first major success of modern therapeutic immunology. Shibasaburo and von Behring immunized guinea pigs with the blood products from animals that had recovered from diphtheria and realized that the same process of heat treating blood products of other animals could treat humans with diphtheria. By 1896, the introduction of diphtheria antitoxin was hailed as `` the most important advance of the ( 19th ) Century in the medical treatment of acute infective disease ''. Prior to the advent of vaccines and antibiotics, specific antitoxin was often the only treatment available for infections such as diphtheria and tetanus. Immunoglobulin therapy continued to be a first line therapy in the treatment of severe respiratory diseases until the 1930s, even after sulfonamides were introduced. This image is from the Historical Medical Library of The College of Physicians of Philadelphia. This displays the administration of diphtheria antitoxin from horse serum to young child, dated 1895. In 1890 antibody therapy was used to treat tetanus, when serum from immunized horses was injected into patients with severe tetanus in an attempt to neutralize the tetanus toxin, and prevent the dissemination of the disease. Since the 1960s, human tetanus immune globulin ( TIG ) has been used in the United States in unimmunized, vaccine - naive or incompletely immunized patients who have sustained wounds consistent with the development of tetanus. The administration of horse antitoxin remains the only specific pharmacologic treatment available for botulism. Antitoxin also known as heterologous hyperimmune serum is often also given prophylactically to individuals known to have ingested contaminated food. IVIG treatment was also used successfully to treat several victims of toxic shock syndrome, during the 1970s tampon scare. Antibody therapy is also used to treat viral infections. In 1945, hepatitis A infections, epidemic in summer camps, were successfully prevented by immunoglobulin treatment. Similarly, hepatitis B immune globulin ( HBIG ) effectively prevents hepatitis B infection. Antibody prophylaxis of both hepatitis A and B has largely been supplanted by the introduction of vaccines ; however, it is still indicated following exposure and prior to travel to areas of endemic infection. In 1953, human vaccinia immunoglobulin ( VIG ) was used to prevent the spread of smallpox during an outbreak in Madras, India, and continues to be used to treat complications arising from smallpox vaccination. Although the prevention of measles is typically induced through vaccination, it is often treated immuno - prophylactically upon exposure. Prevention of rabies infection still requires the use of both vaccine and immunoglobulin treatments. During a 1995 Ebola virus outbreak in the Democratic Republic of Congo, whole blood from recovering patients, and containing anti-Ebola antibodies, was used to treat eight patients, as there was no effective means of prevention, though a treatment was discovered recently in the 2013 Ebola epidemic in Africa. Only one of the eight infected patients died, compared to a typical 80 % Ebola mortality, which suggested that antibody treatment may contribute to survival. Immune globulin or immunoglobulin has been used to both prevent and treat reactivation of the herpes simplex virus ( HSV ), varicella zoster virus, Epstein - Barr virus ( EBV ), and cytomegalovirus ( CMV ). Fda licensed immunoglobulins The following immunoglobulins are the immunoglubulins currently approved for use for infectious disease prophylaxis and immunotherapy, in the United States. FDA approved products for passive immunization and immunotherapy Disease Product Source Use Botulism Specific equine IgG horse Treatment of wound and food borne forms of botulism, infant botulism is treated with human botulism immune globulin ( BabyBIG ). Cytomegalovirus ( CMV ) hyper - immune IVIG human Prophylaxis, used most often in kidney transplant patients. Diphtheria Specific equine IgG horse Treatment of diphtheria infection. Hepatitis A, measles Pooled human Ig human serum Prevention of Hepatitis A and measles infection, treatment of congenital or acquired immunodeficiency. Hepatitis B Hepatitis B Ig human Post-exposure prophylaxis, prevention in high - risk infants ( administered with Hepatitis B vaccine ). ITP, Kawasaki disease, IgG deficiency Pooled human IgG human serum Treatment of ITP and Kawasaki disease, prevention / treatment of opportunistic infection with IgG deficiency. Rabies Rabies Ig human Post-exposure prophylaxis ( administered with rabies vaccine ). Tetanus Tetanus Ig human Treatment of tetanus infection. Vaccinia Vaccinia Ig human Treatment of progressive vaccinia infection including eczema and ocular forms ( usually resulting from smallpox vaccination in immunocompromised individuals ). Varicella ( chicken - pox ) Varicella - zoster Ig human Post-exposure prophylaxis in high risk individuals. = = Passive transfer of cell - mediated immunity The one exception to passive humoral immunity is the passive transfer of cell - mediated immunity, also called adoptive immunization which involves the transfer of mature circulating lymphocytes. It is rarely used in humans, and requires histocompatible ( matched ) donors, which are often difficult to find, and carries severe risks of graft - versus - host disease. This technique has been used in humans to treat certain diseases including some types of cancer and immunodeficiency. However, this specialized form of passive immunity is most often used in a laboratory setting in the field of immunology, to transfer immunity between `` congenic '', or deliberately inbred mouse strains which are histocompatible. Advantages and disadvantages An individual 's immune response of passive immunity is `` faster than a vaccine '' and can instill immunity in an individual that does not `` respond to immunization '', often within hours or a few days. Another advantage to passive immunity is that maternal antibodies that are passed to the newborn during nursing boosts the newborn 's immune system having lasting effects on the baby 's health such as decreased risk of obesity. A disadvantage to passive immunity is that producing antibodies in a laboratory is expensive and difficult to do. In order to produce antibodies for infectious diseases, there is a need for possibly thousands of human donors to donate blood or immune animals ' blood would be obtained for the antibodies. Patients who are immunized with the antibodies from animals may develop serum sickness due to the proteins from the immune animal and develop serious allergic reactions. Antibody treatments can be time consuming and are given through an intravenous injection or IV, while a vaccine shot or jab is less time consuming and has less risk of complication than an antibody treatment. Passive immunity is effective, but ephemeral ( lasting a short amount of time ). See also Active immunity Immunity ( medical ) References Jump up ^ `` Vaccines : Vac - Gen / Immunity Types ''. www.cdc.gov. Retrieved 2015 - 11 - 20. ^ Jump up to : Microbiology and Immunology On - Line Textbook : USC School of Medicine Jump up ^ `` Passive Immunization - Infectious Diseases ''. Merck Manuals Professional Edition. Retrieved 2015 - 11 - 12. Jump up ^ Kalenik, Barbara ; Sawicka, Róża ; Góra - Sochacka, Anna ; Sirko, Agnieszka ( 2014 - 01 - 01 ). `` Influenza prevention and treatment by passive immunization ''. Acta Biochimica Polonica. 61 ( 3 ) : 573 -- 587. ISSN 1734 - 154X. PMID 25210721. Jump up ^ Lambert, Paul - Henri, Margaret Liu and Claire - Anne Siegrist Can successful vaccines teach us how to induce efficient protective immune responses ? ( Full text - html ) Nature Medicine 11, S54 - S62 ( 2005 ). ^ Jump up to : Janeway, Charles ; Paul Travers ; Mark Walport ; Mark Shlomchik ( 2001 ). Immunobiology ; Fifth Edition. New York and London : Garland Science. ISBN 0 - 8153 - 4101 - 6... Jump up ^ `` Centers for Disease Control and Prevention '' ( PDF ). Jump up ^ `` Natural Passive Immunity - Boundless Open Textbook ''. Boundless. Retrieved 2015 - 11 - 12. Jump up ^ `` WHO Exclusive breastfeeding ''. www.who.int. Retrieved 2016 - 06 - 06. Jump up ^ Mucosal Immunology. ISBN 9780124158474. Jump up ^ `` prophylactically ''. ^ Jump up to : Keller, Margaret A. and E. Richard Stiehm Passive Immunity in Prevention and Treatment of Infectious Diseases Clinical Microbiology Reviews, October 2000, p. 602 - 614, Vol. 13, No. 4 Jump up ^ Immunity Types from Centers for Disease Control and Prevention. Page last updated : May 19, 2014 Jump up ^ Baxter, David ( 2007 - 12 - 01 ). `` Active and passive immunity, vaccine types, excipients and licensing ''. Occupational Medicine. 57 ( 8 ) : 552 -- 556. ISSN 0962 - 7480. PMID 18045976. doi : 10.1093 / occmed / kqm110. Jump up ^ Dolman, C.E. ( 1973 ). `` Landmarks and pioneers in the control of diphtheria. ''. Can. J. Public Health. 64 : 317 -- 36. Jump up ^ Silverstein, Arthur M. ( 1989 ) History of Immunology ( Hardcover ) Academic Press. Note : The first six pages of this text are available online at : ( Amazon.com easy reader ) ^ Jump up to : `` Passive Immunization -- History of Vaccines ''. www.historyofvaccines.org. Retrieved 2015 - 11 - 20. Jump up ^ ( Report ) ( 1896 ). `` Report of the Lancet Special Commission on the relative strengths of diphtheria antitoxic serums ''. Lancet. 148 ( 3803 ) : 182 -- 95. doi : 10.1016 / s0140 - 6736 ( 01 ) 72399 - 9. Jump up ^ Shapiro, Roger L. MD ; Charles Hatheway, PhD ; and David L. Swerdlow, MD Botulism in the United States : A Clinical and Epidemiologic Review Annals of Internal Medicine. 1 August 1998 Volume 129 Issue 3 Pages 221 - 228 Jump up ^ `` Centers of Disease Control and Prevention '' ( PDF ). Jump up ^ Casadevall, A., and M.D. Scharff. 1995. Return to the past : the case for antibody - based therapies in infectious diseases. Clin. Infect. Dis. 21 : 150 - 161 Jump up ^ Mupapa, K., M. Massamba, K. Kibadi, K. Kivula, A. Bwaka, M. Kipasa, R. Colebunders, and J.J. Muyembe - Tamfum on behalf of the International Scientific and Technical Committee. 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J. Infect. Dis. 179 ( Suppl. ) : S18 - S23 Jump up ^ Samuel Baron MD ( 1996 ) Table 8 - 2. U.S. Licensed Immunoglobulin For Passive Immunization Medical Microbiology Fourth Edition The University of Texas Medical Branch at Galveston Jump up ^ `` Breastfeeding Overview ''. WebMD. Retrieved 2015 - 11 - 20. Jump up ^ `` Centers for Disease Control and Prevention '' ( PDF ). Immunology : lymphocytic adaptive immune system and complement Lymphoid Antigens Antigen Superantigen Allergen Hapten Epitope Linear Conformational Mimotope Antigen presentation / Professional APCs : Dendritic cell Macrophage B cell Immunogen Antibodies Antibody Monoclonal antibodies Polyclonal antibodies Autoantibody Microantibody Polyclonal B cell response Allotype Isotype Idiotype Immune complex Paratope Immunity vs. tolerance action : Immunity Autoimmunity Alloimmunity Allergy Hypersensitivity Inflammation Cross-reactivity inaction : Tolerance Central Peripheral Clonal anergy Clonal deletion Tolerance in pregnancy Immunodeficiency Immunogenetics Affinity maturation Somatic hypermutation Clonal selection V ( D ) J recombination Junctional diversity Immunoglobulin class switching MHC / HLA Lymphocytes Cellular T cell Humoral B cell NK cell Substances Cytokines Opsonin Cytolysin Breastfeeding Main Article Breastfeeding Anatomy, Physiology and Immunolgy Anti inflammatory agents in breast milk Areola Areolar gland ( gland of Montgomery ) Breast Breast anatomy Breast crawl Breast milk Breastfeeding and medications Dysphoric milk ejection reflex Frenulum of tongue Galactose Human milk oligosaccharide Hypothalmic - pituitary - prolactin axis Latching on Lactation suppression Lactiferous duct Lactose Milk Overactive let - down Oxytocin Passive immunity Prolactin Prolacin modulator Colostrum Lactation Nipple Mammary gland Mammary alveoli Mammary lobule Disorders and Difficulties Blocked milk duct Breastfeeding difficulties Breast engorgement Cracked nipple Mastitis Neonatal jaundice Breastfeeding infertility Breastfeeding and HIV Lactation failure Prolactinoma Culture and Support Breastfeeding advocacy Breastfeeding in art Breastfeeding in public Breastfeeding in the United States Breastfeeding organizations Breastfeeding promotion Child 's Right to Nurse Act Diana West ( lactation consultant ) History and culture of breastfeeding Human milk bank Human milk banking in North America International Breastfeeding Symbol Jack Newman ( doctor ) International Breast Milk Project La Leche League Lactation room Lactivism Mothers ' rights Pat Shelly Amy Spangler Mary Rose Tully World Breastfeeding Week Roles Doula Midwifery Lactation consultant Lactation Counselor List of breastfeeding activists Wet nurse Equipment used with breastfeeding Breast pump Extended breastfeeding Haberman Feeder Nursing bra Nursing chair Supplemental nursing system Other topics Baby - led weaning Weaning Retrieved from `` https://en.wikipedia.org/w/index.php?title=Passive_immunity&oldid=799466251 '' Categories : Immune system Immunology Preventive medicine Antibodies Talk Contents About Wikipedia Dansk Deutsch 한국어 Nederlands 日本 語 Српски / srpski Edit links This page was last edited on 7 September 2017, at 22 : 06. Text is available under the Creative Commons Attribution - ShareAlike License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia ® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. About Wikipedia

Question: an example of artificially acquired passive immunity is
Answer: high levels of antibodies specific to a pathogen or toxin (obtained from humans, horses, or other animals) are transferred to non-immune persons through blood products that contain antibodies